Valuation: Gan & Lee Pharmaceuticals.

Market Cap 43.71B 6.51B 5.72B 5.37B 4.91B 9.18B 624B 9.25B 64.54B 25.02B 318B 24.46B 23.92B 1,031B P/E 2026 *
31x
P/E 2027 * 27.3x
Enterprise Value 40.51B 6.04B 5.3B 4.98B 4.55B 8.51B 578B 8.57B 59.82B 23.19B 295B 22.67B 22.17B 956B EV / Sales 2026 *
8.13x
EV / Sales 2027 * 6.87x
Free-Float
57.83%
Yield 2026 *
0.32%
Yield 2027 * 0.36%
1 day-1.50%
1 week+6.51%
Current month+6.54%
1 month+7.32%
3 months+28.28%
6 months+30.68%
Current year+7.89%
1 week 68.78
Extreme 68.78
75.99
1 month 65.1
Extreme 65.1
75.99
Current year 51.51
Extreme 51.51
79.99
1 year 51.51
Extreme 51.51
82.25
3 years 32.1
Extreme 32.1
82.25
5 years 30.53
Extreme 30.53
83.38
10 years 30.53
Extreme 30.53
204.41
Manager TitleAgeSince
Chief Executive Officer 46 2025-05-29
Director of Finance/CFO 44 2026-03-08
Chief Tech/Sci/R&D Officer - 2026-03-08
Director TitleAgeSince
Chairman 78 1998-06-16
Director/Board Member 49 2009-12-31
Director/Board Member 44 2015-09-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Sell

Director

-10,000 0.0019%
9/3/26 Sell

Executive/Senior Manager

-3,000 0.0006%
9/2/26 Sell

Executive/Senior Manager

-1,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.50%+6.51%+1.82%+67.98% 6.61B
+0.29%+1.76%+39.23%-3.75% 80.07B
+3.38%+17.89%+620.07%+89.83% 72.7B
-0.07%+2.70%-10.41%-28.96% 60.45B
-1.80%-3.05%-14.24%+26.38% 46.24B
+0.38%+1.82%+3.86%+166.50% 45.97B
-0.47%+3.45%+64.60%-11.14% 33.62B
-0.32%-2.63%+47.65%+111.51% 25.26B
-3.48%+3.80%+5.00%+155.90% 22.95B
-0.64%-2.20%+57.40%+97.29% 15.44B
Average -0.44%+5.36%+81.50%+67.15% 40.93B
Weighted average by Cap. +0.15%+6.70%+125.82%+52.10%

Financials

2026 *2027 *
Net sales 4.98B 743M 652M 613M 560M 1.05B 71.15B 1.05B 7.36B 2.85B 36.27B 2.79B 2.73B 118B 5.74B 856M 751M 706M 645M 1.21B 81.95B 1.21B 8.48B 3.29B 41.78B 3.21B 3.14B 135B
Net income 1.44B 214M 188M 177M 162M 302M 20.52B 304M 2.12B 823M 10.46B 804M 787M 33.91B 1.64B 244M 214M 201M 184M 343M 23.34B 346M 2.41B 936M 11.9B 915M 895M 38.58B
Net Debt -3.2B -477M -419M -394M -360M -673M -45.71B -678M -4.73B -1.83B -23.31B -1.79B -1.75B -75.57B -4.28B -637M -559M -526M -481M -898M -61.05B -905M -6.32B -2.45B -31.12B -2.39B -2.34B -101B
Logo Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals is a China-based company primarily engaged in the research, development, production, and sales of insulin analogue active pharmaceutical ingredients and injectable formulations. The Company’s main products include glargine insulin injection, lispro insulin injection, mixed protamine zinc lispro insulin injection, aspart insulin injection, aspart 30 insulin injection, and mixed protamine human insulin injection. The Company is also engaged in the provision of medical device products, including reusable pen insulin injectors, non-reusable pen injectors, disposable injection pen needles, and disposable insulin pen needles. The Company distributes its products within the domestic market and to overseas markets.
Employees
5,309
Date Price Change Volume
26-09-23 CN¥73.44 -1.50% 10,264,630
26-09-23 CN¥74.56 +5.47% 16,535,899
26-09-22 CN¥70.69 -0.99% 6,837,889
26-09-21 CN¥71.40 +3.61% 9,909,770
26-09-18 CN¥68.91 -0.33% 6,638,423
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
74.56CNY
Average target price
83.00CNY
Spread / Average Target
+11.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 603087 Stock